Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019

Q3 FY22 results · Oct–Dec 2021

Jubilant Pharmova reported revenue from operations of ₹1,310.53 crore (down 26.0% from Q3 FY21) and net profit of ₹50.80 crore (down 83.6% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY22	Q3 FY21	YoY	Q2 FY22	QoQ
Revenue from operations	1,310.53	1,771.34	−26.0%	1,657.45	−20.9%
Other income	5.91	3.59	+64.6%	4.45	+32.8%
Total income	1,316.44	1,774.93	−25.8%	1,661.90	−20.8%
Profit before share of associates & JVs and tax	70.20	343.15	−79.5%	209.43	−66.5%
Share of profit/(loss) of associates & JVs	0.03	(3.10)		(1.39)
Net profit for the period	50.80	309.83	−83.6%	142.64	−64.4%
Attributable to shareholders of the company	50.99	309.93	−83.5%	142.84	−64.3%
EPS, basic (₹)	3.20	19.46	−83.6%	8.97	−64.3%
Net margin (%)	3.9	17.5		8.6

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY22	Q3 FY21	YoY	Q2 FY22	QoQ
Revenue from operations	18.67	828.94	−97.7%	20.03	−6.8%
Other income	8.58	12.21	−29.7%	106.08	−91.9%
Total income	27.25	841.15	−96.8%	126.11	−78.4%
Profit before tax	(6.22)	80.99	Turned loss	94.12	Turned loss
Net profit for the period	(5.34)	64.65	Turned loss	88.08	Turned loss
EPS, basic (₹)	(0.34)	4.06	Turned loss	5.53	Turned loss
Net margin (%)	-28.6	7.8		439.7

Consolidated

Filed with BSE: 04 Feb 2022, 17:23 IST
Board meeting: 04 Feb 2022
Period: 01 Oct 2021 to 31 Dec 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 04 Feb 2022, 17:23 IST
Board meeting: 04 Feb 2022
Period: 01 Oct 2021 to 31 Dec 2021
Review status: Unaudited
Source: XBRL filing on BSE